Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3408 - Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: the “Gastric Life” nomogram

Date

09 Sep 2017

Session

Poster display session

Presenters

Filippo Pietrantonio

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

F. Pietrantonio1, F. Barretta2, V. Fanotto3, M. Niger1, F. Morano1, F. Bergamo4, N. Silvestris5, L. Fornaro6, R. Bordonaro7, M. Baretti8, D. Santini9, G. Tomasello10, L. Antonuzzo11, S. Noventa12, A. Avallone13, S. Di Donato14, E. Maiello15, F. De Vita16, R. Miceli2, G. Aprile17

Author affiliations

  • 1 Department Of Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Department Of Medical Statistics, Biometry And Bioinformatics, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Medical Oncology, AOU Santa Maria della Misericordia, 33100 - Udine/IT
  • 4 Department Of Medical Oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 5 Medical Oncology, Istituto Tumori “Giovanni Paolo II”, 70124 - Bari/IT
  • 6 Medical Oncology, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 7 Medical Oncology, Azienda Ospedaliera ARNAS Garibaldi, 95100 - Catania/IT
  • 8 Medical Oncology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 9 Department Of Oncology, Campus Bio-Medico di Roma, 128 - Roma/IT
  • 10 Medical Oncology, Istituti Ospitalieri di Cremona, 26100 - Cremona/IT
  • 11 Medical Oncology, Azienda Ospedaliera Careggi, 50139 - Firenze/IT
  • 12 Medical Oncology, Fondazione Poliambulanza, Istituto Ospedaliero, 25124 - Brescia/IT
  • 13 Medical Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 14 "sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Azienda USL Toscana Centro, 591000 - Prato/IT
  • 15 Medical Oncology, IRCCS Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT
  • 16 Oncologia Medica, Dipartimento Di Internistica Clinica E Sperimentale “f. Magrassi”,, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 17 Department Of Oncology, San Bortolo General Hospital, 36100 - Vicenza/IT
More

Resources

Abstract 3408

Background

The estimation of life expectancy of mGC pts in the second-line setting may be biased by the absence of objective prognostic tools to be used for enrollment in clinical trials and for decision making in the daily practice. The availability of evidence-based second-line treatment options highlights the need of nomograms/prognostic scores which may assist clinicians in refining pts’ clinical selection in the salvage setting. The aim of this study was to build a nomogram for predicting the individual 12-weeks overall survival (OS) of mGC pts starting a second-line treatment.

Methods

At 26 Italian Institutions, 320 mGC patients receiving second-line chemotherapy, ramucirumab or paclitaxel-ramucirumab were used as developing set. Putative prognostic variables (age, gender, ECOG PS, T resection, Lauren’s histotype, primary anatomic site, synchronous presentation, number and location of metastatic sites, PFS and response to 1-line, LDH, neutrophils/lymphocytes ratio) were selected using a random forest model and included in a Cox multivariable model from which the nomogram was derived. The nomogram performance was evaluated by means of calibration plot and discriminative ability (Harrell’s C index).

Results

Three variables were selected and included in the nomogram: ECOG PS (P 

Conclusions

Our nomogram may be a useful tool to predict 12-weeks life expectancy in mGC pts candidates for second-line therapy. Based on 3 easy-to-collect variables, the” Gastric Life” nomogram may improve second-line pts’ selection and assist researchers for the enrollment in clinical trials.

Clinical trial identification

Legal entity responsible for the study

Filippo Pietrantonio

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.